Last updated: June 21, 2022. Click here to view log of changes to our data and website.
Corticosteroids, interleukin-6 inhibitors receptor antagonists, and janus kinase inhibitors probably reduce mortality and confer other important benefits in patients with severe covid-19. Molnupiravir probably reduces admission to hospital in patients with non-severe covid-19.
Much of the evidence remains very low certainty and we therefore anticipate future studies evaluating drugs for prophylaxis may change the results for SARS-CoV-2 infection, admission to hospital and mortality outcomes. Both hydroxychloroquine and vitamin C combined with zinc probably increase adverse effects.
There is no clear eﬀect of bamlanivimab, convalescent plasma, or IVIG on patient- important outcomes. Properly evaluating the safety and eﬃcacy of humoral and cellular therapies for the treatment of covid-19 will requires data from additional large randomised trials.